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Summary Steroids are widely used for the treatment of leprosy reactions. The 
effectiveness of steroid treatment is variable, with only 60% of patients regaining 
nerve function. Sequential skin biopsy specimens, obtained from 1 5  patients with 
type 1 (reversal) reactions, have been studied to document the cytokine profile and 
cellularity of the lesions. All of the patients were placed on a standard course of 
steroids after the first biopsy. Subsequent biopsies were performed seven, 28 and 1 80 
days later. The specimens were stained for interferon-'Y (IFN'Y), interleukin- 1 2  (IL-
1 2) and inducible nitric oxide synthase (iNOS). After the first biopsy, all patients 
were placed on a standard reducing course of steroids beginning at 30 mg daily. 
By day 7, treatment with prednisolone showed little effect on the cellularity and 
cytokine profiles. However, by day 28, significant decreases of IFN-'Y, IL- 1 2  and 
iNOS were found for most patients. Some patients maintained cytokine production at 
day 28 and even at day 1 80. These data illustrate the strong Thl profile of type 1 
reactional lesions, the relatively slow response to therapy, and the continuing activity 
after treatment with steroids for 1 80 days. The variation of individual responses 
emphasizes their importance. Additional prospective studies will be required to 
determine whether patients with high intra-lesional levels of cytokine are at risk of 
recurrent reactions. The need for studies both of different glucocorticoids and of other 
non-steroidal immunosuppressants for the treatment of reactions is discussed. 
This paper focuses on the use of steroid treatment for leprosy reactions and neuritis, 
considering first the outcome of steroid treatment, and then the mechanisms by which 
steroids work at the molecular level. Some data from a study being carried out in Hyderabad, 
India, on the effects of steroid treatment on the cytokine profiles of reactional skin lesions are 
presented, and the implications of developing better treatment of reactions are discussed. 
Corticosteroids are widely used in both hospital and field settings for the treatment of 
leprosy reactions and nerve damage. Semi-standardized, reducing courses of steroids, lasting 
for 1 2  weeks, are recommended by the World Health Organisation. ! However, the data with 
respect to the outcome of treatment with steroids show a range of outcomes. In an outpatient 
clinic in Hyderabad, India, only 50% of patients with reactions were judged to have improved 
nerve function after steroid treatment.2 
Recently, data have become available from prospective field studies . In Bangladesh, full 
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recovery was found in only 33% of motor and 37% of sensory nerves, whereas 3 1  % of motor 
and 32% of sensory nerves failed to improve, and 12% of motor and 13% of sensory nerves 
deteriorated in the course of steroid treatment. 3 The response to treatment is also affected by 
the length of time that the neuritis has been present. In an Ethiopian study, 88% of patients 
who developed acute neuritis after treatment, and whose neuritis was detected and treated 
promptly, made a full recovery. However, among the patients with chronic neuritis, only 5 1  % 
of the affected nerves recovered fully.4 
Steroids have both physicochemical and genomic effects. Their non-genomic effects are 
either receptor-mediated or mediated via non-specific physicochemical activity.s These 
actions are probably responsible for the immediate actions of steroids, such as reducing 
oedema. The genomic actions of steroids involve the glucocorticoid crossing cell membranes, 
attaching to glucocorticoid receptors, and binding to glucocorticoid response elements on the 
genomic DNA. It is this mechanism that affects cytokine production.6 Multiple effects of 
steroids on cytokine production have been described, with actions proposed at the levels of 
transcription and translation, and in the stability of mRNA and protein products .7 The 
principal mechanism is thought to be inhibition of NF-KB-induced transcription of cytokine­
mRNAs. A number of cytokine genes have the same NF-KB binding sites in their promoter 
regions, and the production of several pro-inflammatory cytokines, including tumour 
necrosis factor-a (TNFa)8 interleukin-2 (IL-2),9 IL- 1 2 1O and interferon--y (IFN-y) I 1 are down­
regulated by glucocorticoids. The same mechanism has been shown to be involved in the 
down-regulation of expression of inducible nitric oxide synthase (iNOS) by corticosteroids. 1 2  
Increased degradation of  iNOS has also been noted a s  an effect of  steroids. 
There have been few examinations of the effect of steroids on local cytokine production 
within inflammatory lesions in vivo. In this present study, skin lesions of leprosy patients with 
type 1 reactions were sampled sequentially to determine the effects of treatment with 
prednisolone on local cell population and cytokine profiles. Another aim was to determine 
whether steroids switch off the Thl response associated with type 1 reactions .  The detailed 
methods and results of this study are being reported elsewhere. 1 3  
Methods and results 
Biopsies were performed on days 0, 7 ,  28 and 1 80 from 1 5  (six BT and nine BL) patients with 
clinically diagnosed and histologically confirmed type 1 reactions. After the first biopsy, all 
patients were placed on a standard reducing course of steroids, starting at 30 mg daily. 
Staining for IFN-y, IL- 1 2  and iNOS proteins and CD3, CD4 and CD8 cell types, was 
performed on cryosections, employing monoclonal antibodies in a two-stage immunoperox­
idase technique. 14 Positive staining was visualized using 3,3-diaminobenzidine. The location 
and amount of staining for each cell and cytokine at each time-point was assessed. 
In the day 0 biopsy specimen, all patients demonstrated granulomata with strongly 
positive staining for IFN-y, IL- 1 2  and iNOS. Treatment with prednisolone had little effect on 
the cellularity and cytokine profiles at day 7. By day 28, however, significant decreases were 
found for the cellularity of the lesions and for production of IFN-y, IL- 1 2  and iNOS in most 
but not all patients. No correlations were found between clinical severity of disease type (BT 
or BL) and cytokine production. Only five patients were biopsied at 1 80 days, all of them BL 
patients. Three of these patients still had very active lesions, all with increased cytokine levels 
compared to the levels at 28 days. 
Discussion 
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This study illustrates the strong Th I -like cytokine-profile within reactional lesions . Although 
prednisolone decreases the production of IFN'Y, IL- 1 2  and iNOS, it does so slowly. This is 
rather surprising, given the rapid action of glucocorticoids (even the genomic actions require 
only a few hours) .  1 5 Furthermore, many BL patients still have considerable activity in their 
lesions after 6 months. It will be important to identify the factors that drive the ongoing 
recruitment of cells into the lesions. These data also illustrate the need to study lesions within 
individual patients over a long time-span. 
What are the implications of these observations for the development of medical therapies 
for reactions? Damage to nerves might be reduced if drugs with a more rapid effect on the 
cellularity and lesional cytokine profile were used for treatment. Recent work on the relative 
genomic and non-genomic potencies of glucocorticoids suggests that glucocorticoids with a 
high ratio of non-genomic to genomic activity may be needed for early, high-level 
immunosuppression. 15 It may be that methylprednisolone, which has such a ratio, is a 
better drug for initiating treatment. 
In BL patients, there may be a need for prolonged immunosuppression. It is interesting 
that, in the Ethiopian study, patients with chronic neuritis had only a 5 1  % improvement of 
nerve function; it may be that these patients represent a subgroup characterized by ongoing 
immune mediated activity in their lesions. Further prospective studies are needed to 
determine whether patients with high or prolonged intralesional cytokine production are at 
risk of recurrent reactions. 
There has been no formal experience in leprosy of using non-steroidal immuno­
suppressants to treat reactions .  As part of the INFIR collaboration, studies of two such 
immunosuppressants, used extensively in the treatment of other immune-mediated disease 
processes, are beginning. In these studies, cyclosporin A and azathioprine will be compared 
to prednisolone in the management of reactions .  Cyclosporin A inhibits transcription of IL-2 
mRNA, thereby blocking proliferation of T cells, whereas azathioprine inhibits synthesis of 
nucleic acids, and acts much more slowly. Combinations of immunosuppressants have been 
used with success in other immune-mediated conditions such as rheumatoid arthritis . 1 6  The 
experience gained with other agents should be examined so that, where appropriate, the new 
agents may be subjected to clinical trial in leprosy reactions and neuritis .  
It may be that the ideal immunosuppressant for leprosy reactions will be a combination of 
therapies-a drug with a fast-acting component that will switch inflammation off more 
rapidly than does prednisolone, and a longer-acting immunosuppressant that will ameliorate 
ongoing inflammation in patients who are at risk of chronic inflammation. It is important that 
clinically based studies of molecular predictors of outcomes in leprosy reactions be carried 
out, and that appropriate new drugs be tried for the large numbers of patients who do not 
respond to steroids. 
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DISCUSSION 
Dr Sampaio : We carried out a similar study, in which we biopsied the lesions of patients 
in reaction and carried out PCR on the lesions. Steroid therapy brings about a decrease of 
expression of TNFa mRNA, but an increase of expression of IL- lO mRNA. In the case of 
patients with ENL who are treated with thalidomide, one does not see the increase of expression 
of IL- lO  mRNA. 
